Barbara Jobst, MD, PhD. Photo by Mark Washburn
Barbara C. Jobst, MD, Dr. med, has been named the new chair of the Department of Neurology for Dartmouth-Hitchcock and Dartmouth’s Geisel School of Medicine. Previously, Jobst served as vice chair of Neurology and section chief of Adult Neurology. She has directed the Epilepsy Center at D-H and is the Louis and Ruth Frank Professor of Neuroscience at Geisel. She succeeds Jeffrey A. Cohen, MD, who retired as department chair in January 2021. Jobst is the first woman to serve as chair of Neurology at D-H and Geisel.
“I am thrilled to be chosen as the next Neurology chair as I see it as an opportunity shape and educate the next generation of neurological researchers and physicians,” Jobst said. “It will be my job to make the department even more successful than it already is, and I am excited to work with my colleagues at D-H and Geisel to achieve that goal.”
Areas of brain damage called white matter hyperintensities are commonly linked to vascular health problems. They have also been linked to Alzheimer s disease. Now a new study has shown that white matter hyperintensities are also found in frontotemporal dementia. The study is published in the February 17, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology.
Healthy Living: Chemo Brain - 9 & 10 News 9and10news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 9and10news.com Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Period Activity
February 11, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 11, 2021
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth quarter and full year ended December 31, 2020 and reviewed recent business highlights.
“We’re very pleased with the 2020 commercial performance for our marketed products, and expect steady and continued growth in 2021 across our product portfolio, driven by improved disease awareness, new patient finding, and geographic expansion. In the fourth quarter we celebrated the regulatory approvals of our third and fourth commercial medicines: OXLUMO, in the EU and U.S.; and Leqvio, in the EU. We also reported positive topline results from the HELIOS-A Pha